Sona Nanotech Inc (CSE:SONA, OTCQB:SNANF) CEO David Regan speaks to Thomas Warner from Proactive about his ambitious plans for the Canadian company's proprietary gold nanorods.
He says that Sona Nanotech is currently "building a mountain of data" to support the potential use of its technology in innovative cancer treatments, having recently announced that it had received the third set of results of an independent assessment of its nanorods from the U.S. National Cancer Institute’s Nanotechnology Characterization Laboratory (“NCL”).